| Date | Title | | | 05/31/18 | KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference| CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 31, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
that it will present a corporate overview at the Jefferies Healthcare
Conference on Friday, June 8, 2018, at 9:30 a.m. ET in New York, NY.
A live webcast of the presentatio... |
|  | | 05/29/18 | KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018| – KVD900 Data Accepted for Late Breaking Poster Session –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 29, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
data from a poster presentation at the European Academy of Allergy and
Clinical Immunology (EAACI) Congress 2018 in Mu... |
| | | 05/16/18 | KalVista Pharmaceuticals Recognizes HAE Day| – A Global Awareness Day for a Rare Life-Threatening Condition –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 16, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
recognition of patient organizations from around the world holding a
global awareness day for the condition her... |
| | | 05/02/18 | KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting| – Oral Plasma Kallikrein Inhibitor Blocks VEGF-induced Retinal
Vascular Hyperpermeability –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
data in support of the Company’s development activities in diabetic
macular edema (DME) from an oral pr... |
| | | 04/18/18 | KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting| – Oral Plasma Kallikrein Inhibitor Data in a Preclinical Model of
Retinal Edema to be Presented –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
that data in support of KalVista’s ongoing development in diabetic
macular edema (DME) has been... |
| | | 03/16/18 | KalVista Pharmaceuticals Reports Fiscal Third Quarter Results| – Enrollment Ongoing for a Phase 2 Clinical Trial of KVD001 in
Diabetic Macular Edema (“DME”) and a Phase 1 Clinical Trial for the
Second Candidate in the Oral Hereditary Angioedema (“HAE”)
Portfolio –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today r... |
| | | 03/05/18 | KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
that it will present a corporate overview at the ROTH Conference on
Monday, March 12, 2018, at 2:30 p.m. PT in Orange County, CA.
A live webcast of the presentation may be accessed on the Investors... |
| | | 01/05/18 | KalVista Pharmaceuticals Commences Two Clinical Trials| – Data Expected for Phase 2 Clinical Trial of KVD001 in Diabetic
Macular Edema Patients in the Second Half of 2019 –
– Second Oral Hereditary Angioedema Candidate Begins Phase 1 Clinical
Trial –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today an... |
| |
|
